Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. - Wikidata - wikimedia - TriplyDB

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

http://www.wikidata.org/entity/Q34551761

about

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer Regulation of ERBB3/HER3 signaling in cancer Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner Translating neoadjuvant therapy into survival benefits: one size does not fit all.Disentangling multidimensional spatio-temporal data into their common and aberrant responses Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.Tailoring chimeric ligands for studying and biasing ErbB receptor family interactions Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification.AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.Dynamical modeling of uncertain interaction-based genomic networks.A Systems Biology Approach in Therapeutic Response Study for Different Dosing Regimens-a Modeling Study of Drug Effects on Tumor Growth using Hybrid Systems Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.Two dimensions in targeting HER2.Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer

P2860

Q26862550-D80D1A7A-0297-402E-AA2A-1B7BF4F05AD7 Q27024334-1AE9E329-FFC5-43F6-9A9A-CCACFCAB5804 Q27315979-1C76423B-591C-4FA9-B6C8-1C44007704AC Q27342948-5F07EA40-910D-496E-BEDF-4C0C367847A8 Q28834261-638B569A-BC29-4163-8950-34691E968A86 Q30251738-F60F7EB7-336D-4219-A42E-EAB8EC684FBC Q30938497-55CED721-F7E2-4E60-99F0-B097EE05EC21 Q30997919-739D55B8-87A9-4631-AD43-12F5A903A612 Q33275064-859C3D5B-374E-496A-9EDE-3FD5475C36BD Q33591690-0A17C94C-A768-45C0-AD4A-A79B3C705DAB Q33597447-F130AEAE-5AEC-4F30-B1A7-75F60E0B7845 Q33601610-ACF5203F-2F81-44ED-B61B-F14F5870636F Q34225871-E3DC965E-25DC-4E81-92D8-B0E45C6535E5 Q34349389-0604340B-C671-4498-89DC-3E35E1AF1AC5 Q34470371-3D4D5F6E-49D6-4BD5-B326-8D8B07106248 Q34511038-819C6A5D-6E2A-47C9-963A-77C3E4D4DA33 Q34720797-B5A55469-389C-4E8C-A329-B387AB8E469C Q34960206-73A83C36-64D9-4708-A67B-F4DA4CE00328 Q34974436-CA68C352-643E-4A1E-989B-DAECE0B0739F Q35145024-8FFE5001-3EB2-49AA-ABF6-E8F83E386A1E Q35176075-31EF5969-9EEA-439F-9A62-FEB5E0DB3F3F Q35479665-390A92CF-F64B-4D53-9CD4-ED34F06B20CC Q35533503-67694C83-0881-4901-8952-EA430791F05F Q35535547-D8ACB5F5-7DDA-460D-94A2-450493DDD3AE Q35562967-1B20A456-573F-4A60-BDF4-FC1177BB9DBE Q35591518-5CDA348C-52CF-4545-AD6D-AC31F546B76E Q35693389-187DC30A-0268-4B5B-AA6D-5BC6D1A23A6A Q35779022-86D4ED7B-80F0-4115-BA08-22FD8F317AE0 Q35794214-863CB547-A026-4739-B425-53F34753A917 Q35817902-02CACE29-7A9B-4D3C-9DC4-892F8CA8DC17 Q35846880-478B8E7C-55D4-437D-B7CA-3C82B807CB22 Q35861503-6FA54181-8283-4611-9DCA-D280B35E04AA Q35889621-ECE0047F-BE8D-4B0B-8111-EE6B128CE54C Q35890128-68637E6F-2C11-4BAE-A4B8-854F4262BBC3 Q35895143-C71E112D-7388-440A-A0C6-9DC3193A018B Q35895370-CCAED7BC-E368-4E3A-B95F-38E9B5C02C71 Q35967385-CCBE4505-E571-4F44-AC32-EDD90BA73DE2 Q36088788-3611A164-B76C-4DC4-A7D1-2C81040B0BFE Q36250585-4AC7052D-4F2A-464D-A8A1-2F172A9AC178 Q36306149-8281D755-3AE2-4EAB-ADD0-87A37258414D

P2860

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

http://www.wikidata.org/entity/Q34551761

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@ast

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@en

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@nl

type

label

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@ast

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@en

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@nl

prefLabel

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@ast

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@en

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@nl

P1433

Q34551761-EDEB6A70-7201-4D8E-B824-523917265A10

P1476

Q34551761-D3347E3B-232B-4538-B057-C6CFC5880079

P2093

Q34551761-5CDB8E2D-CA64-4CF4-A4C6-4CA29F07E01F

Q34551761-5EDCFB24-C3C5-4DB8-A89C-FBA38BB55999

Q34551761-65C3D41A-D67A-48F7-A2D0-B5C83AA48111

Q34551761-7E778159-44FC-48E8-BEEB-C8CBC53CDE1E

Q34551761-9BA98D10-07BF-4E36-A00E-FA8D0A5D7393

Q34551761-B2BD8D03-CE4E-465C-8D88-631CD9BE22A7

Q34551761-C21F7E59-D447-4309-B0A3-446F520F155A

Q34551761-E37C82A6-07DE-435A-8824-8BD7CD31E2F7

Q34551761-E6C65B34-997E-4D25-9E8A-B5FE95C14996

Q34551761-F6E8BE2D-F6E2-41BF-B2E9-E871E73EC2D9

P2860

Q34551761-0431C11C-29C8-42F7-BEA6-AA3B27981C12

Q34551761-06DEEE49-9009-4DED-92A2-1C6F1CCE6DC6

Q34551761-09B92F67-3F4A-41FC-8589-D5C17D3E97EA

Q34551761-0C088589-A0DB-47E9-80D1-5E6D9C1D91C0

Q34551761-0CBE0BCF-3BC6-47BF-9470-DF6E8AAC9E14

Q34551761-0CF94AAC-C08F-4BBD-BCA1-1E8E7D18C8D0

Q34551761-0E224CB9-9C54-4F23-B898-3477002066CA

Q34551761-1065888B-31E3-42A1-8333-5AFDAC4BE525

Q34551761-16104219-8B48-4DAF-A69F-06ED18812AD7

Q34551761-1822CB84-B19A-4CF5-AB17-D77645AACA96

P304

Q34551761-5F03C332-E944-4CA1-AD7F-7B49D222C92D

P31

Q34551761-F3D86ECD-EECB-4297-AC76-24EE8B699BCA

P356

Q34551761-895F6BD7-8991-4F6F-985A-AF5B49FC95D8

P407

Q34551761-9F34F9C7-3461-4B24-B50A-7CF4CFEA572C

P433

Q34551761-63C886A4-8280-436E-9CD6-BFA574325A71

P478

Q34551761-0A7AF9F4-36BE-46CA-B5A4-C3BAC4AE94AF

P577

Q34551761-746BF240-847B-4338-9665-2E40458506C3

P5875

Q34551761-B52A5A5F-B3D6-45B5-AEB2-73BA4AC117C3

P698

Q34551761-62081049-08FE-4D11-8347-934BBAFEEEFC

P932

Q34551761-3CDCC9EB-BCB0-4CAE-AB63-2D38D250A58A

P356

SCITRANSLMED.3000389

P1433

Science Translational Medicine

P1476

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

@en

P2093

Byron Hann

http://www.w3.org/2001/XMLSchema#string

Deepika Ahuja

http://www.w3.org/2001/XMLSchema#string

Dhara N Amin

http://www.w3.org/2001/XMLSchema#string

Donghui Wang

http://www.w3.org/2001/XMLSchema#string

Jimmy A Blair

http://www.w3.org/2001/XMLSchema#string

Kevan M Shokat

http://www.w3.org/2001/XMLSchema#string

Kevin M Koch

http://www.w3.org/2001/XMLSchema#string

Mark M Moasser

http://www.w3.org/2001/XMLSchema#string

Martin McMahon

http://www.w3.org/2001/XMLSchema#string

Natalia Sergina

http://www.w3.org/2001/XMLSchema#string

P2860

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

Mechanism of activation and inhibition of the HER4/ErbB4 kinase

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer

P304

16ra7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3000389

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43049770

http://www.w3.org/2001/XMLSchema#string

P698

20371474

http://www.w3.org/2001/XMLSchema#string

P932

3033659

http://www.w3.org/2001/XMLSchema#string